Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13442807 | 0.84 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL1560612 | 0.84 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL11462046 | 0.83 | CYP2D6 (0.43) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL341361 | 0.81 | CYP3A4 (0.55) | CYP2D6CYP1A2SRCDPP4LMNA | |
| SCHEMBL19439080 | 0.81 | CYP3A4 (0.55) | CYP2D6CYP1A2SRCDPP4LMNA | |
| SCHEMBL5306707 | 0.80 | CYP2D6 (0.52) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL1955 | 0.80 | ESR1 (0.53) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL29816355 | 0.80 | CYP2D6 (0.52) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL29016375 | 0.79 | ACE (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL4445835 | 0.79 | TSHR (0.57) | SMN1; SMN2F2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MED LTD (GB) | 2026-05-07 | — | — | US | claimed |
| EP-4598592-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | Owlstone Medical Limited (GB) | 2025-08-13 | — | — | EP | claimed |
| CN-120152745-A | Compounds and their use for detecting diseases in exhaled breath of a subject | 奥斯通医疗有限公司 | 2025-06-13 | — | — | CN | claimed |
| WO-2024074813-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MEDICAL LIMITED (GB) | 2024-04-11 | — | — | WO | claimed |
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | claimed |
| WO-2024044554-A1 | VHH ANTIBODY CONJUGATES WITH HETEROARYL CHELATORS | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | claimed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | claimed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | claimed |
| WO-2021184020-A1 | METHODS OF TREATING NEUROINFLAMMATION | CODIAK BIOSCIENCES, INC. (US) | 2021-09-16 | — | — | WO | claimed |
| WO-2014089146-A1 | COMPOSITIONS AND METHODS FOR IN VIVO DELIVERY OF ANTISENSE COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | claimed |
| EP-2651420-A2 | PEPTIDE-BASED IN VIVO SIRNA DELIVERY SYSTEM | Arrowhead Research Corporation (US) | 2013-10-23 | — | — | EP | claimed |
| US-8501930-B2 | Peptide-based in vivo siRNA delivery system | Arrowhead Madison Inc. (US) | 2013-08-06 | — | — | US | claimed |
| US-20120165393-A1 | Peptide-Based In Vivo siRNA Delivery System | Arrowhead Madison Inc. (US) | 2012-06-28 | — | — | US | claimed |
| WO-2012083185-A2 | PEPTIDE-BASED IN VIVO SIRNA DELIVERY SYSTEM | ARROWHEAD RESEARCH CORPORATIONS (US) | 2012-06-21 | — | — | WO | claimed |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MED LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-4598592-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | Owlstone Medical Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| CN-1321715-A | Adhesive of fixing matrix for microelectronic device | NAT STARCH & CHEMICAL INVEST H (US) | 2001-11-14 | — | — | CN | disclosed |
| CN-1253969-A | Circuit element prepared with allylated amide compound | NAT STARCH CHEM INVEST (US) | 2000-05-24 | — | — | CN | disclosed |
| EP-0317956-A2 | Anti-tumor prodrugs | Bristol-Myers Squibb Company (US) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165393-A1 | Peptide-Based In Vivo siRNA Delivery System | VIP, RNASE1, APLNR | CYP2D6 4663/4885CYP1A2 4864/4885PKM 3686/4885 |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | BRCA1, L3MBTL1, LMNA | CYP2D6 1797/4885CYP1A2 2022/4885PKM 1739/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | CYP2D6 4482/4885CYP1A2 4876/4885PKM 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.